Organization (Industry)
CORDIS US CORP.
ClinicalTrials.gov lists CORDIS US CORP. as lead sponsor of 78 trials. It has 2 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 2 registered with a 2026 start date. The dashed outline is the pace from the 2 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo Cordis US Corp, via Wikimedia Commons, CC BY-SA 4.0. Shown to identify the organization; it may be a registered trademark.
This page covers CORDIS US CORP.: 78 lead-sponsored trials and 2 legal-entity registrations.
Disease areas (30)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Coronary Disease | 58 |
| Coronary Artery Disease | 50 |
| Atherosclerosis | 12 |
| Peripheral Arterial Disease | 9 |
| Aortic Aneurysm | 7 |
Showing 5 of 30 disease areas.
Trials by start year as sponsor or collaborator (23)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 2 |
| 2023 | 1 |
| 2022 | 7 |
| 2020 | 1 |
| 2019 | 2 |
| 2018 | 1 |
| 2015 | 2 |
| 2014 | 1 |
| 2012 | 2 |
Showing 10 of 23 years.
Recruitment duration, a model prediction: none of the 78 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (2)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Clopidogrel & Aspirin, Prasugrel & Aspirin | 1 |
| PCI (0.25% marcaine+ 2.0 μg/mL of adrenaline + %0.9 saline) | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 82% hit target (n=11) | 56% on time (n=9) |
Journals published in (46)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Circulation | 29 |
| Journal of the American College of Cardiology | 25 |
| Journal of vascular surgery | 25 |
| The New England journal of medicine | 12 |
| American heart journal | 11 |
Showing 5 of 46 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 969 | 4 | 2025-11-04 |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| VAI | 17 |
FDA recalls (61)
Shown in this order: most recent first.
| Product | Classification | Initiated |
|---|---|---|
| Cordis, REF C10040ML, Smart Control Vascular Stent System ILIAC, 10mm X 40mm 6F, SterileEO, Rx Only | Class II | 2025-03-04 |
| Cordis, REF: C09060ML, Smart Control Vascular Stent System ILIAC, 9mm X 60mm 6F, SterileEO, Rx Only | Class II | 2025-03-04 |
| Vista Brite Tip, Judkins Right 4, REF SM7504, JR3 VBT (Special) 110 cm 6F. Guiding catheter is intended for use for intravascular introduction of interventional/diagnostic devices into the coronary or peripheral vascular systems. | Class II | 2025-02-07 |
| MYNXGRIP 5F, REF MX5021, Vascular Closure Device (VCD). Used to seal femoral arterial and femoral venous access sites. | Class II | 2023-11-28 |
| MYNXGRIP 6F/7F, REF MX6721, Vascular Closure Device (VCD). Used to seal femoral arterial and femoral venous access sites | Class II | 2023-11-28 |
Showing 5 of 61 recalls.
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 1 | 2006-02-06 |
Manufacturing and distribution sites (2)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Cordis US Corp. | Miami Lakes, US | FDA | |
| Cordis US Corp. | Santa Clara, US | FDA |
Organization relationships (1)
| Related organization | Relationship | Evidence |
|---|---|---|
| Iqvia Holdings Inc. | Uses vendor | 1 |
Latest dated events (1,147)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-06-23 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-01-31 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-11-24 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-11-04 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-10-30 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 1,147 events.
Biomarker capability evidence (44)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| BTK | Trial collaborator | Named in trial inclusion criteria |
| CEACAM5 | Trial sponsor | Named in trial inclusion criteria |
| CLU | Trial collaborator | Named in trial inclusion criteria |
| DEGS1 | Trial sponsor | Named in trial inclusion criteria |
| DEGS1 | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 44 evidence rows.
On Scientist.com
CORDIS US CORP. is listed as a research supplier in the Scientist.com network.
Service areas
Cordis Corporation, a Johnson & Johnson company, focuses on technological innovation, development, and manufacturing of stents, catheters, and guidewires for interventional medicine.
- Website
- www.cordis.com
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.
Work with Cordis Corporation on Scientist.com
For prices, more details, or to contact Cordis Corporation, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.